KHK7791 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Mar 15, 2021 → Sep 27, 2021
NCT ID
NCT04766398About KHK7791 + Placebo
KHK7791 + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04766398. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 14 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (12)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04766398 | Phase 3 | Completed |
| NCT04767581 | Phase 3 | Completed |
| NCT03864458 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia